Opivibo, the first cancer immunotherapy drug in China, approved by the Chinese National Drug Administration and Supervision Agency for indications of treatment non-small cell lung cancer with history

By Cancer

Opivibo, the first cancer immunotherapy drug in China, approved by the Chinese National Drug Administration and Supervision Agency for indications of treatment non-small cell lung cancer with history

News Release | Ono Pharmaceutical Co., Ltd.

http://www.ono.co.jp/jpnw/PDF/n18_0618_2.pdf

China National Drug Administration Approves Country’s First Immuno-Oncology Agent, Opdivo (nivolumab injection), for Previously Treated Non-Small Cell Lung Cancer (NSCLC) | BMS Newsroom

https://news.bms.com/press-release/corporatefinancial-news/china-national-drug-administration-approves-countrys-first-imm

More from tokioX :

  1. Kyoto University: Utilizing iPS cells for cancer immunotherapy: Proliferating killer T cells
  2. US FDA: Takeda Pharmaceutical’s Lung Cancer Treatment Approval: Exkivity
  3. CiRA: Developed universal iPS cells: Cancer immunotherapy
  4. Cancer treatment: Boron neutron capture therapy/BNCT treatment start: Developed by Kyoto University/Sumitomo Heavy Industries
  5. Shimadzu: Mass Spectrometry, New Cancer Immunotherapy Development: Providence Cancer Institute
  6. Cancer Therapy: Kyoto University, New Method Detecting Aggressively Attacking Cancer Cells – Human iPS-derived “Killer T Cells”
  7. FDA: Eisai ‘s “Rembima” approved as a hepatocellular cancer drug